Objective To observe the effect of glutamine on gut barrier function and antioxidative capacity in rats with radiation damage. Methods A total of 30 healthy Wistar male rats were randomly divided into three groups: control group, GLN enriched group(+GLN) and GLN free group( GLN). Rats in control and GLN group were fed with a basic diet, while 3% GLN was added into the diet of the +GLN group. On the 15th day, rats in GLN and +GLN groups received 9.0 Gy 60 Co ? irradiation in total body. The rate of the gut bacterial translocation and the level of endotoxin, GSH and SOD in the serum were determined at the end of the experiment. Results The rate of bacterial translocation and serum endoxin level were significantly lower in +GLN than in GLN, and GSH and SOD levels in serum were significantly higher in +GLN than in GLN. Conclusion Glutamine supplement is helpful to protect the gut barrier function and improve the antioxidation capacity in rats with radiation injury.

We aroused students' learning interest,adjusted teaching contents,played the appropriate role of teachers,optimized teaching means and carried out comprehensive evaluation based on special characteristics of the optional course environmental eugenics and the knowledge structure of students to improve the teaching quality and teaching effect as well as make this course contribute to comprehensive ability of medical students.

Aim To investigate the effect of salvianolic acid B (Sal B)on c-Jun N-terminal kinase (JNK)ac-tivation and apoptosis of INS-1 cells induced by inter-mittent high glucose.Methods INS-1 cells were pre-incubated with Sal B for 24 h,followed by exposure to intermittent high glucose (IHG,11.1 mmol·L-1 12 h,33. 3 mmol·L-1 12 h)for 72 h.Cell viability was assessed by MTT assay and cell apoptosis was evalua-ted by flow cytometry.Glucose induced insulin secre-tion capacity and intracellular reactive oxygen species (ROS)contents were measured by enzyme linked im-munosorbent assay (ELISA)and a fluorescent probe DCFH-DA,respectively.Levels of JNK activation and PDX-1 protein expression were determined by Western blot analysis.Results Sal B significantly alleviated IHG-induced cell injury and apoptosis,with glucose induced insulin secretion capacity improved evidently (P<0.05 or P<0.01).Preincubation with Sal B no-tably decreased intracellular ROS and JNK activation in INS-1 cells,while the level of PDX-1 protein was in-creased markedly (P<0.05 or P<0.01 ).Conclu-sion Sal B is capable of ameliorating IHG-induced cell injury and apoptosis in INS-1 cells,which might be derived from suppression of JNK activation and up-regulation of PDX-1 protein expression.

OBJECTIVETo conduct a systematic review of the safety and efficacy of enhanced recovery after surgery(ERAS) program in perioperative management of pancreaticoduodenectomy.

METHODSA computerized search was performed in databases including PubMed, Embase, Medline, Web of Science, Cochrane Library, CNKI, Wanfang and VIP for randomized controlled trials (RCTs) or clinical controlled trials (CCTs) describing an ERAS program in patients undergoing pancreaticoduodenectomy published between January 1966 and May 2014. After assessment of methodological quality and data extraction, meta-analysis was performed using RevMan 5.2.0 software.

RESULTSSix RCTs and 8 CCTs including 2565 patients were selected for this study, including the study group(n=1366) and the control group (n=1199). Compared with the control group, the study group had a shorter length of hospital stay(WMD=-3.67, 95% CI:-5.66--1.68, P<0.05), lower postoperative complication rate(OR=0.73, 95% CI:0.56-0.95, P<0.05) and lower mortality(OR=0.63, 95% CI:0.44-0.91, P<0.05). However, no significant differences existed in mortality, readmission rate and re-operation rate between the two groups.

CONCLUSIONSEnhanced recovery after surgery programme in perioperative management of pancreaticoduodenectomy is safe and effective. But due to the medium quality of the literature. This still need more rigorously designed RCTs to prove the safety and efficiency of ERAS programme for the patients undergoing pancreaticoduodenectomy.

Humans ; Length of Stay ; Pancreaticoduodenectomy ; Postoperative Complications